Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Jim B who wrote (3191)	7/16/1998 5:52:00 AM
From: R>G>	Read Replies (1) \| Respond to of 5402

Awesome Report JimB I enjoyed very much. Great way to start the day. Bob

To: Jim B who wrote (3191)	7/16/1998 11:41:00 AM
From: dwlima	Read Replies (1) \| Respond to of 5402

very informative post- thanks. one question though. if sgnc receives funding to carry out the work at batelle....why do i not see any funds received in their reported statements?

To: Jim B who wrote (3191)	7/16/1998 3:48:00 PM
From: jmt	Respond to of 5402

JimB. I enjoyed reading your post. A couple of questions please. >>>He has a BA,MBNA,PHD Business Administration<<<< Does the Dr. hold a medical degree or just business degree's?? >>>Under this he was able to get the first generation product of their blood substitute approved by the Japanese FDA. The ONLY person to ever do this with this type of product. Many many people were tested on this 1st gen. product with no complications. However, do to a problem with paperwork through the Japanese FDA being handled improperly, SGNC was forced to refocus its efforts in the American market.<<< I can't tell buy this if the product was/is actually approved by the Japanese FDA. It seems unlikely that a paperwork error could result in the banning of a product that could save so many lives. >>>>These investors have of course been getting shares in return. But by far, we've seen no evidence of any stock dilution<<<< Just a clarification. Issuing stock to raise capital IS dillution. This statement is grossly misleading, but I am sure it was not intentional. >>>>Also, he mentioned that SGNC in 1994 had merged with a VERY small company that had been around for decades. We didn't really get to touch on why they merged, but he did say that that company was pretty much dead along with its stock price. The shares were transferred into SGNC stock and many of these people have waited 4 years for prices like we've seen recently on SGNC; thus, some of them are most likely selling.<<<< This VERY small company must have gotten quite a few shares to depress the price of this stock so significantly. I guess they must not understand (similar to Green Cross, the Japanese FDA, and most major research institutions) the true value of this product. >>>At first, I thought that BATTELLE had given SGNC the money to do this, but actually there are private investors that have funded SGNC now for some time and it is they who gave SGNC the money to pay BATTELLE to do continued research on PHER-02 (SGNC's 2nd generation product).<<< Here is where I sense a credibility issue. Your two most prominent rumors when pushing this stock were the credibility of Bastelle and their desire to fund the effort resulting from their faith in the product, and secondly the institutional investors (of which none of influence were on hand in Utah) who are lining up to invest. Finally: >>>Buyout for SGNC in 6months to 1 year continues to be VERY strong and LIKELY.<<<< Don't know how you can say this with any confidence given the product has not finished any meaningful evaluation. jmt

To: Jim B who wrote (3191)	7/16/1998 5:15:00 PM
From: Janice Shell	Read Replies (2) \| Respond to of 5402

Dr. Drees has about 30years of experience in the marketplace. His background initially was that of a business analyst. And now you say that the "company" consists of Drees and one other person. Where's the, uh, SCIENCE here? Who does research? Oh my GOD. Until I read this I was willing to believe that SGNC was a real company. Not a successful one, but one that perhaps showed promise. A company doing serious research. Gimme a break.